Caricamento...
Characterizing new users of NSAIDs before and after rofecoxib withdrawal
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT: • Public concern regarding the cardiovascular safety of the COX-2 inhibitors began with the withdrawal of rofecoxib from the market in September 2004. • Since then, a myriad of evidence has pointed towards an adverse cardiovascular effect of other COX-2 inhi...
Salvato in:
| Autori principali: | , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Blackwell Publishing Ltd
2007
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2203243/ https://ncbi.nlm.nih.gov/pubmed/17054665 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2125.2006.02784.x |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|